Xetra
02.04.26 | 17:35
303,25 Euro
-0,49 % -1,50
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 300,45 | 301,05 | 02.04. | |
| 300,70 | 302,60 | 02.04. |
► 01.04.: | | | | | | | | |
► Aktueller AMGEN Börsenkurs + Xetra-Orderbuch
► Aktueller AMGEN Börsenkurs + Xetra-Orderbuch
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 349,00 | 10 | |||
| 338,10 | 1 | |||
| 307,00 | 4 | |||
| 305,50 | 50 | |||
| 305,35 | 50 | |||
| 305,15 | 77 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/amg.htm [/URL] | ||||
| 50 | 304,15 | |||
| 27 | 304,10 | |||
| 50 | 304,05 | |||
| 4 | 302,20 | |||
| 50 | 289,30 | |||
| 1.053 | 0,000 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 1.234 | 0,156 | 192 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 15:30:30 | 302,75 | 49 |
| 09:04:40 | 307,30 | 1 |
| Tagesumsatz Xetra | -1,50 -0,49 % | 72 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | RBC Capital reiterates Amgen stock rating on diversified growth | 3 | Investing.com | ||
| AMGEN Aktie jetzt für 0€ handeln | |||||
| Do | RBC Capital bestätigt "Outperform"-Rating für Amgen angesichts diversifizierter Wachstumstreiber | 3 | Investing.com Deutsch | ||
| Do | Zai Lab Enters Global Collaboration with Amgen to Explore Novel ADC and BiTE Combination Therapy | 7 | AASTOCKS | ||
| Mi | Zai Lab gains after clinical trial pact with Amgen | 10 | Seeking Alpha | ||
| Mi | FDA points to liver injury with Amgen's Tavneos | 3 | pharmaphorum |
1 2 3 4 5 Weiter >>
318 Nachrichten in den letzten 12 Monaten
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| Do | Celyad Oncology Reports Full Year 2025 Financial Results and Business Highlights | Business Wire | Regulatory News:
Celyad Oncology (Euronext: CYAD) (the "Company"), today announces its financial results for the fiscal year ended December 31, 2025, and provides a business update.
2025 business... ► Artikel lesen | |
| Do | Resverlogix Corp.: Resverlogix Corp. Announces Issuance of MCTO by ASC | Newsfile | Calgary, Alberta--(Newsfile Corp. - April 2, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") today announces the issuance of a management cease trade order ("MCTO") by the... ► Artikel lesen | |
| Do | EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Group (EN) | EQS Voting Rights Announcement: Evotec SE
Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide... ► Artikel lesen | |
| Do | Sharp Therapeutics Corp.: Sharp Therapeutics Announces Closing of Third Tranche of Unsecured Convertible Note Offering | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 2, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it has... ► Artikel lesen | |
| Do | OS Therapies: OS Therapies Completes $5.25M Registered Direct Offering Primarily with Pre-Existing High-Net-Worth Investors | Newsfile | Company expects approximately $2 million in non-dilutive VAT refunds from wholly owned U.K. subsidiary in 2Q-26Company expects to receive approximately $2 million in non-dilutive R&D tax credits... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AMGEN INC finden Sie auf Wallstreet Online.